Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 12 2021
15 12 2021
Historique:
received:
16
06
2021
revised:
18
08
2021
accepted:
27
09
2021
pubmed:
3
10
2021
medline:
15
1
2022
entrez:
2
10
2021
Statut:
ppublish
Résumé
The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic Patients had progressed after next-generation androgen receptor-directed and taxane-based therapies for mCRPC and had BRCA alterations identified by central sequencing of plasma and/or tissue samples or local genomic testing. Concordance of plasma/tissue BRCA status and objective response rate and prostate-specific antigen (PSA) response rates were summarized. TRITON2 enrolled 115 patients with BRCA Plasma, tissue, and local testing of mCRPC patients can be used to identify men with BRCA
Identifiants
pubmed: 34598946
pii: 1078-0432.CCR-21-2199
doi: 10.1158/1078-0432.CCR-21-2199
pmc: PMC8678310
mid: NIHMS1746918
doi:
Substances chimiques
Indoles
0
Poly(ADP-ribose) Polymerase Inhibitors
0
rucaparib
8237F3U7EH
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
6677-6686Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092629
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA180995
Pays : United States
Commentaires et corrections
Type : CommentOn
Informations de copyright
©2021 American Association for Cancer Research.
Références
JAMA Oncol. 2021 Jun 04;:
pubmed: 34086042
Expert Rev Mol Diagn. 2017 Mar;17(3):209-215
pubmed: 28129709
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
JCO Precis Oncol. 2019 Dec;3:1-9
pubmed: 35100678
Mol Cancer Res. 2020 Apr;18(4):517-528
pubmed: 31996469
Breast Cancer Res Treat. 2017 Jun;163(2):383-390
pubmed: 28281021
Genet Med. 2020 Sep;22(9):1517-1523
pubmed: 32439974
JAMA Oncol. 2016 Dec 01;2(12):1598-1606
pubmed: 27148695
J Clin Invest. 2020 Apr 1;130(4):1743-1751
pubmed: 31874108
J Natl Cancer Inst. 2017 Dec 01;109(12):
pubmed: 29206995
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Prostate. 2014 Feb;74(2):210-6
pubmed: 24132735
Int J Mol Sci. 2019 May 27;20(10):
pubmed: 31137764
Clin Genitourin Cancer. 2016 Dec;14(6):485-493
pubmed: 27246360
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Expert Rev Mol Diagn. 2016 Dec;16(12):1251-1257
pubmed: 27737606
JAMA. 2017 Oct 3;318(13):1272-1274
pubmed: 28973237
JCO Precis Oncol. 2019;3:
pubmed: 31218271
Lung Cancer. 2017 Sep;111:190-194
pubmed: 28838392
JAMA Oncol. 2021 Jan 01;7(1):107-110
pubmed: 33151258
Cancer Discov. 2021 Jan;11(1):6
pubmed: 33208392
Cell Stem Cell. 2018 Feb 1;22(2):157-170
pubmed: 29395053
Prostate Cancer Prostatic Dis. 2014 Dec;17(4):325-31
pubmed: 25091040
JAMA Oncol. 2021 Jan 1;7(1):111-112
pubmed: 33151257
PLoS One. 2015 Oct 13;10(10):e0139440
pubmed: 26460686
Cancer Res. 2009 May 15;69(10):4434-42
pubmed: 19366804
Cancer. 2018 Mar 1;124(5):1008-1015
pubmed: 29266381
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Ann Oncol. 2021 Jul;32(7):896-905
pubmed: 33836265
Urology. 2000 Mar;55(3):323-7
pubmed: 10699601
Clin Cancer Res. 2005 Nov 15;11(22):8109-13
pubmed: 16299243
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
J Mol Diagn. 2018 Sep;20(5):686-702
pubmed: 29936259
Mol Cancer Res. 2016 Oct;14(10):898-908
pubmed: 27422709